Iovance Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
CEOFrederick G. Vogt
CEOFrederick G. Vogt
Employees838
Employees838
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2007
Founded2007
Employees838
Employees838
IOVA Key Statistics
Market cap776.18M
Market cap776.18M
Price-Earnings ratio-1.85
Price-Earnings ratio-1.85
Dividend yield—
Dividend yield—
Average volume13.01M
Average volume13.01M
High today$2.30
High today$2.30
Low today$2.10
Low today$2.10
Open price$2.26
Open price$2.26
Volume13.69M
Volume13.69M
52 Week high$12.51
52 Week high$12.51
52 Week low$1.64
52 Week low$1.64
IOVA News
Simply Wall St 5d
A Look at Iovance Biotherapeutics’s Valuation Following FDA Approval of Amtagvi for Solid TumorsIovance Biotherapeutics (IOVA) made headlines after securing the first FDA approval for an immune cell therapy targeting solid tumors with its drug, Amtagvi. On...
The Motley Fool 5d
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc HealthIs there a glimmer of hope for either of these underperforming healthcare companies? Here's a great way to earn strong market returns over the long term: Ident...
Analyst ratings
58%
of 12 ratingsBuy
58.3%
Hold
33.3%
Sell
8.3%
People also own
Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.